Current Report Filing (8-k)
June 09 2017 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
June 6,
2017
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34236
|
11-3054851
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
35 Wilbur Street
|
11563
|
Lynbrook, NY
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code:
516.593.7000
N/A
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of
the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
2
Introductory Comment
Throughout this Current Report on Form 8-K, the terms we,
us, our and Company refer to BioSpecifics Technologies Corp.
Item 7.01 Regulation FD Disclosure
Officers and representatives of the Company will present to
various investors and stockholders beginning June 6, 2017 using the presentation
materials furnished as Exhibit 99.1 hereto and which are incorporated herein by
reference.
The information in this report (including Exhibit 99.1) shall
not be deemed to be filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to
the liability of that section, and shall not be incorporated by reference into
any registration statement or other document filed under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: June 6, 2017
BioSpecifics Technologies Corp.
By:
/s/ Thomas L.
Wegman
Name: Thomas L. Wegman
Title: President
4
EXHIBIT INDEX
5
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Sep 2023 to Sep 2024